1
|
Stalin J, Coquoz O, Jeitziner Marcone R, Jemelin S, Desboeufs N, Delorenzi M, Blot-Chabaud M, Imhof BA, Ruegg C. Targeting of the NOX1/ADAM17 Enzymatic Complex Regulates Soluble MCAM-Dependent Pro-Tumorigenic Activity in Colorectal Cancer. Biomedicines 2023; 11:3185. [PMID: 38137406 PMCID: PMC10740863 DOI: 10.3390/biomedicines11123185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2023] [Revised: 11/16/2023] [Accepted: 11/27/2023] [Indexed: 12/24/2023] Open
Abstract
The melanoma cell adhesion molecule, shed from endothelial and cancer cells, is a soluble growth factor that induces tumor angiogenesis and growth. However, the molecular mechanism accounting for its generation in a tumor context is still unclear. To investigate this mechanism, we performed in vitro experiments with endothelial/cancer cells, gene expression analyses on datasets from human colorectal tumor samples, and applied pharmacological methods in vitro/in vivo with mouse and human colorectal cancer cells. We found that soluble MCAM generation is governed by ADAM17 proteolytic activity and NOX1-regulating ADAM17 expression. The treatment of colorectal tumor-bearing mice with pharmacologic NOX1 inhibitors or tumor growth in NOX1-deficient mice reduced the blood concentration of soluble MCAM and abrogated the anti-tumor effects of anti-soluble MCAM antibodies while ADAM17 pharmacologic inhibitors reduced tumor growth and angiogenesis in vivo. Especially, the expression of MCAM, NOX1, and ADAM17 was more prominent in the angiogenic, colorectal cancer-consensus molecular subtype 4 where high MCAM expression correlated with angiogenic and lymphangiogenic markers. Finally, we demonstrated that soluble MCAM also acts as a lymphangiogenic factor in vitro. These results identify a role for NOX1/ADAM17 in soluble MCAM generation, with potential clinical therapeutic relevance to the aggressive, angiogenic CMS4 colorectal cancer subtype.
Collapse
Affiliation(s)
- Jimmy Stalin
- Department of Pathology and Immunology, University of Geneva Medical School, Rue Michel Servet 1, CH-1211 Geneva, Switzerland; (S.J.); (B.A.I.)
- Department of Oncology, Microbiology, and Immunology, Faculty of Science and Medicine, University of Fribourg, Chemin du Musée 18, PER17, CH-1700 Fribourg, Switzerland; (O.C.); (N.D.); (C.R.)
- C2VN, Inserm 1263, Inra 1260, UFR Pharmacie, Aix-Marseille University, 27 Bd J. Moulin, 13005 Marseille, France;
| | - Oriana Coquoz
- Department of Oncology, Microbiology, and Immunology, Faculty of Science and Medicine, University of Fribourg, Chemin du Musée 18, PER17, CH-1700 Fribourg, Switzerland; (O.C.); (N.D.); (C.R.)
| | - Rachel Jeitziner Marcone
- Bioinformatics Core Facility, SIB Swiss Institute of Bioinformatics, CH-1015 Lausanne, Switzerland; (R.J.M.); (M.D.)
| | - Stephane Jemelin
- Department of Pathology and Immunology, University of Geneva Medical School, Rue Michel Servet 1, CH-1211 Geneva, Switzerland; (S.J.); (B.A.I.)
| | - Nina Desboeufs
- Department of Oncology, Microbiology, and Immunology, Faculty of Science and Medicine, University of Fribourg, Chemin du Musée 18, PER17, CH-1700 Fribourg, Switzerland; (O.C.); (N.D.); (C.R.)
| | - Mauro Delorenzi
- Bioinformatics Core Facility, SIB Swiss Institute of Bioinformatics, CH-1015 Lausanne, Switzerland; (R.J.M.); (M.D.)
| | - Marcel Blot-Chabaud
- C2VN, Inserm 1263, Inra 1260, UFR Pharmacie, Aix-Marseille University, 27 Bd J. Moulin, 13005 Marseille, France;
| | - Beat A. Imhof
- Department of Pathology and Immunology, University of Geneva Medical School, Rue Michel Servet 1, CH-1211 Geneva, Switzerland; (S.J.); (B.A.I.)
| | - Curzio Ruegg
- Department of Oncology, Microbiology, and Immunology, Faculty of Science and Medicine, University of Fribourg, Chemin du Musée 18, PER17, CH-1700 Fribourg, Switzerland; (O.C.); (N.D.); (C.R.)
| |
Collapse
|
2
|
Kocabey S, Chiarelli G, Acuna GP, Ruegg C. Ultrasensitive and multiplexed miRNA detection system with DNA-PAINT. Biosens Bioelectron 2023; 224:115053. [PMID: 36608362 DOI: 10.1016/j.bios.2022.115053] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2022] [Revised: 12/27/2022] [Accepted: 12/28/2022] [Indexed: 12/31/2022]
Abstract
MiRNAs hold great potential as biomarkers for the early detection and monitoring of diseases based on their differential expression profiles. Therefore, the sensitive, specific and accurate detection of miRNAs represents an emerging new tool to improve diagnosis and treatment of several diseases, cancer in particular. DNA origami-based miRNA detection is particularly advantageous as it allows to incorporate multiple attachment sites to capture different target miRNAs at the nanoscale. In this work, we present a DNA origami nanoarray system providing distance-dependent recognition of miRNAs by applying super-resolution microscopy technique; DNA-PAINT (point accumulation for imaging in nanoscale topography). The sensor can detect up to 4 miRNAs either separately or in combination based on the relative distance to the boundary markers on the structure using a single imager strand. The detection is highly sensitive, with a limit of detection down to the low femtomolar range (11 fM - 388 fM) and has a large dynamic range up to 10 nM without need for amplification. Moreover, our detection system can discriminate single base mismatches with low false positive rates. Using our strategy, we demonstrate the detection of endogenous miRNAs from cell extracts of cancer cell lines and plasma from breast cancer patients. Overall, we developed an ultrasensitive and amplification-free, DNA-PAINT imaging-based miRNA detection method using DNA origami nanoarray system for the detection of breast-cancer associated miRNAs which potentially provides a sensitive and accurate alternative to the current multiplexed diagnostic technologies.
Collapse
Affiliation(s)
- Samet Kocabey
- Laboratory of Experimental and Translational Oncology, Department of Oncology, Microbiology and Immunology, Faculty of Science and Medicine, University of Fribourg, Chemin du Musée 18, PER17, 1700, Fribourg, Switzerland.
| | - Germán Chiarelli
- Photonic Nanosystems, Department of Physics, Faculty of Science and Medicine, University of Fribourg, Chemin du Musée 3, PER08, 1700, Fribourg, Switzerland
| | - Guillermo P Acuna
- Photonic Nanosystems, Department of Physics, Faculty of Science and Medicine, University of Fribourg, Chemin du Musée 3, PER08, 1700, Fribourg, Switzerland
| | - Curzio Ruegg
- Laboratory of Experimental and Translational Oncology, Department of Oncology, Microbiology and Immunology, Faculty of Science and Medicine, University of Fribourg, Chemin du Musée 18, PER17, 1700, Fribourg, Switzerland
| |
Collapse
|
3
|
Domljanovic I, Loretan M, Kempter S, Acuna GP, Kocabey S, Ruegg C. DNA origami book biosensor for multiplex detection of cancer-associated nucleic acids. Nanoscale 2022; 14:15432-15441. [PMID: 36219167 PMCID: PMC9612396 DOI: 10.1039/d2nr03985k] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 07/20/2022] [Accepted: 09/03/2022] [Indexed: 06/16/2023]
Abstract
DNA nanotechnology provides a promising approach for the development of biomedical point-of-care diagnostic nanoscale devices that are easy to use and cost-effective, highly sensitive and thus constitute an alternative to expensive, complex diagnostic devices. Moreover, DNA nanotechnology-based devices are particularly advantageous for applications in oncology, owing to being ideally suited for the detection of cancer-associated nucleic acids, including circulating tumor-derived DNA fragments (ctDNAs), circulating microRNAs (miRNAs) and other RNA species. Here, we present a dynamic DNA origami book biosensor that is precisely decorated with arrays of fluorophores acting as donors and acceptors and also fluorescence quenchers that produce a strong optical readout upon exposure to external stimuli for the single or dual detection of target oligonucleotides and miRNAs. This biosensor allowed the detection of target molecules either through the decrease of Förster resonance energy transfer (FRET) or an increase in the fluorescence intensity profile owing to a rotation of the constituent top layer of the structure. Single-DNA origami experiments showed that detection of two targets can be achieved simultaneously within 10 min with a limit of detection in the range of 1-10 pM. Overall, our DNA origami book biosensor design showed sensitive and specific detection of synthetic target oligonucleotides and natural miRNAs extracted from cancer cells. Based on these results, we foresee that our DNA origami biosensor may be developed into a cost-effective point-of-care diagnostic strategy for the specific and sensitive detection of a variety of DNAs and RNAs, such as ctDNAs, miRNAs, mRNAs, and viral DNA/RNAs in human samples.
Collapse
Affiliation(s)
- Ivana Domljanovic
- Laboratory of Experimental and Translational Oncology, Department of Oncology, Microbiology and Immunology, Faculty of Science and Medicine, University of Fribourg, Chemin du Musée 18, PER17, 1700 Fribourg, Switzerland.
| | - Morgane Loretan
- Photonic Nanosystems, Department of Physics, Faculty of Science and Medicine, University of Fribourg, Chemin du Musée 3, PER08, 1700 Fribourg, Switzerland.
| | - Susanne Kempter
- Department of Physics, Ludwig-Maximilians-University, Geschwister-Scholl-Platz 1, 80539 Munich, Germany
| | - Guillermo P Acuna
- Photonic Nanosystems, Department of Physics, Faculty of Science and Medicine, University of Fribourg, Chemin du Musée 3, PER08, 1700 Fribourg, Switzerland.
| | - Samet Kocabey
- Laboratory of Experimental and Translational Oncology, Department of Oncology, Microbiology and Immunology, Faculty of Science and Medicine, University of Fribourg, Chemin du Musée 18, PER17, 1700 Fribourg, Switzerland.
| | - Curzio Ruegg
- Laboratory of Experimental and Translational Oncology, Department of Oncology, Microbiology and Immunology, Faculty of Science and Medicine, University of Fribourg, Chemin du Musée 18, PER17, 1700 Fribourg, Switzerland.
| |
Collapse
|
4
|
Upadhyay N, Tilekar K, Safuan S, Kumar AP, Stalin J, Ruegg C, Ramaa C S. Recent Anti‐angiogenic Drug Discovery Efforts To Combat Cancer. ChemistrySelect 2021. [DOI: 10.1002/slct.202101792] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Affiliation(s)
- Neha Upadhyay
- Department of Pharmaceutical Chemistry Bharati Vidyapeeth's College of Pharmacy Sector 8, CBD Belapur Navi Mumbai 400614 India
| | - Kalpana Tilekar
- Department of Pharmaceutical Chemistry Bharati Vidyapeeth's College of Pharmacy Sector 8, CBD Belapur Navi Mumbai 400614 India
| | - Sabreena Safuan
- Pusat pengajian sains School of Health Sciences Universiti Sains Malaysia Malaysia 16150 Kubang Kerian Kelantan
| | - Alan P. Kumar
- Department of Pharmacology National University of Singapore Singapore
| | - Jimmy Stalin
- Department of Oncology Microbiology, and Immunology University of Fribourg Chemin du Musée 18, PER17, CH 1700 Fribourg Switzerland
| | - Curzio Ruegg
- Department of Oncology Microbiology, and Immunology University of Fribourg Chemin du Musée 18, PER17, CH 1700 Fribourg Switzerland
| | - Ramaa C S
- Department of Pharmaceutical Chemistry Bharati Vidyapeeth's College of Pharmacy Sector 8, CBD Belapur Navi Mumbai 400614 India
| |
Collapse
|
5
|
Stalin J, Garrido-Urbani S, Heitz F, Szyndralewiez C, Jemelin S, Coquoz O, Ruegg C, Imhof BA. Inhibition of host NOX1 blocks tumor growth and enhances checkpoint inhibitor-based immunotherapy. Life Sci Alliance 2019; 2:2/4/e201800265. [PMID: 31249132 PMCID: PMC6599972 DOI: 10.26508/lsa.201800265] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2018] [Revised: 06/13/2019] [Accepted: 06/13/2019] [Indexed: 01/17/2023] Open
Abstract
Blocking NOX1 with the novel small molecule inhibitor GKT771 inhibits tumor growth in mice by targeting tumor lymph/angiogenesis and promoting antitumor immune cells recruitment. GKT771 emerges as a novel and promising anticancer drug worth translating into the clinics. NADPH oxidases catalyze the production of reactive oxygen species and are involved in physio/pathological processes. NOX1 is highly expressed in colon cancer and promotes tumor growth. To investigate the efficacy of NOX1 inhibition as an anticancer strategy, tumors were grown in immunocompetent, immunodeficient, or NOX1-deficient mice and treated with the novel NOX1-selective inhibitor GKT771. GKT771 reduced tumor growth, lymph/angiogenesis, recruited proinflammatory macrophages, and natural killer T lymphocytes to the tumor microenvironment. GKT771 treatment was ineffective in immunodeficient mice bearing tumors regardless of their NOX-expressing status. Genetic ablation of host NOX1 also suppressed tumor growth. Combined treatment with the checkpoint inhibitor anti-PD1 antibody had a greater inhibitory effect on colon carcinoma growth than each compound alone. In conclusion, GKT771 suppressed tumor growth by inhibiting angiogenesis and enhancing the recruitment of immune cells. The antitumor activity of GKT771 requires an intact immune system and enhances anti-PD1 antibody activity. Based on these results, we propose blocking of NOX1 by GKT771 as a potential novel therapeutic strategy to treat colorectal cancer, particularly in combination with checkpoint inhibition.
Collapse
Affiliation(s)
- Jimmy Stalin
- Department of Pathology and Immunology, Medical Faculty, University of Geneva, Geneva, Switzerland .,Department of Oncology, Microbiology and Immunology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland
| | - Sarah Garrido-Urbani
- Department of Pathology and Immunology, Medical Faculty, University of Geneva, Geneva, Switzerland
| | - Freddy Heitz
- Genkyotex S.A Forum 2, Archamps Technopole, Saint-Julien-en-Genevois, France
| | | | - Stephane Jemelin
- Department of Pathology and Immunology, Medical Faculty, University of Geneva, Geneva, Switzerland
| | - Oriana Coquoz
- Department of Oncology, Microbiology and Immunology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland
| | - Curzio Ruegg
- Department of Oncology, Microbiology and Immunology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland
| | - Beat A Imhof
- Department of Pathology and Immunology, Medical Faculty, University of Geneva, Geneva, Switzerland .,Medicity Research Laboratory, University of Turku, Turku, Finland
| |
Collapse
|
6
|
Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, Auerbach R, Augustin HG, Bates DO, van Beijnum JR, Bender RHF, Bergers G, Bikfalvi A, Bischoff J, Böck BC, Brooks PC, Bussolino F, Cakir B, Carmeliet P, Castranova D, Cimpean AM, Cleaver O, Coukos G, Davis GE, De Palma M, Dimberg A, Dings RPM, Djonov V, Dudley AC, Dufton NP, Fendt SM, Ferrara N, Fruttiger M, Fukumura D, Ghesquière B, Gong Y, Griffin RJ, Harris AL, Hughes CCW, Hultgren NW, Iruela-Arispe ML, Irving M, Jain RK, Kalluri R, Kalucka J, Kerbel RS, Kitajewski J, Klaassen I, Kleinmann HK, Koolwijk P, Kuczynski E, Kwak BR, Marien K, Melero-Martin JM, Munn LL, Nicosia RF, Noel A, Nurro J, Olsson AK, Petrova TV, Pietras K, Pili R, Pollard JW, Post MJ, Quax PHA, Rabinovich GA, Raica M, Randi AM, Ribatti D, Ruegg C, Schlingemann RO, Schulte-Merker S, Smith LEH, Song JW, Stacker SA, Stalin J, Stratman AN, Van de Velde M, van Hinsbergh VWM, Vermeulen PB, Waltenberger J, Weinstein BM, Xin H, Yetkin-Arik B, Yla-Herttuala S, Yoder MC, Griffioen AW. Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis 2018; 21:425-532. [PMID: 29766399 PMCID: PMC6237663 DOI: 10.1007/s10456-018-9613-x] [Citation(s) in RCA: 393] [Impact Index Per Article: 65.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
The formation of new blood vessels, or angiogenesis, is a complex process that plays important roles in growth and development, tissue and organ regeneration, as well as numerous pathological conditions. Angiogenesis undergoes multiple discrete steps that can be individually evaluated and quantified by a large number of bioassays. These independent assessments hold advantages but also have limitations. This article describes in vivo, ex vivo, and in vitro bioassays that are available for the evaluation of angiogenesis and highlights critical aspects that are relevant for their execution and proper interpretation. As such, this collaborative work is the first edition of consensus guidelines on angiogenesis bioassays to serve for current and future reference.
Collapse
Affiliation(s)
- Patrycja Nowak-Sliwinska
- Molecular Pharmacology Group, School of Pharmaceutical Sciences, Faculty of Sciences, University of Geneva, University of Lausanne, Rue Michel-Servet 1, CMU, 1211, Geneva 4, Switzerland.
- Translational Research Center in Oncohaematology, University of Geneva, Geneva, Switzerland.
| | - Kari Alitalo
- Wihuri Research Institute and Translational Cancer Biology Program, University of Helsinki, Helsinki, Finland
| | - Elizabeth Allen
- Laboratory of Tumor Microenvironment and Therapeutic Resistance, Department of Oncology, VIB-Center for Cancer Biology, KU Leuven, Louvain, Belgium
| | - Andrey Anisimov
- Wihuri Research Institute and Translational Cancer Biology Program, University of Helsinki, Helsinki, Finland
| | - Alfred C Aplin
- Department of Pathology, University of Washington, Seattle, WA, USA
| | | | - Hellmut G Augustin
- European Center for Angioscience, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany
- Division of Vascular Oncology and Metastasis Research, German Cancer Research Center, Heidelberg, Germany
- German Cancer Consortium, Heidelberg, Germany
| | - David O Bates
- Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham, UK
| | - Judy R van Beijnum
- Angiogenesis Laboratory, Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
| | - R Hugh F Bender
- Department of Molecular Biology and Biochemistry, University of California, Irvine, CA, USA
| | - Gabriele Bergers
- Laboratory of Tumor Microenvironment and Therapeutic Resistance, Department of Oncology, VIB-Center for Cancer Biology, KU Leuven, Louvain, Belgium
- Department of Neurological Surgery, Brain Tumor Research Center, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA
| | - Andreas Bikfalvi
- Angiogenesis and Tumor Microenvironment Laboratory (INSERM U1029), University Bordeaux, Pessac, France
| | - Joyce Bischoff
- Vascular Biology Program and Department of Surgery, Harvard Medical School, Boston Children's Hospital, Boston, MA, USA
| | - Barbara C Böck
- European Center for Angioscience, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany
- Division of Vascular Oncology and Metastasis Research, German Cancer Research Center, Heidelberg, Germany
- German Cancer Consortium, Heidelberg, Germany
| | - Peter C Brooks
- Center for Molecular Medicine, Maine Medical Center Research Institute, Scarborough, ME, USA
| | - Federico Bussolino
- Department of Oncology, University of Torino, Turin, Italy
- Candiolo Cancer Institute-FPO-IRCCS, 10060, Candiolo, Italy
| | - Bertan Cakir
- Department of Ophthalmology, Harvard Medical School, Boston Children's Hospital, Boston, MA, USA
| | - Peter Carmeliet
- Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology and Leuven Cancer Institute (LKI), KU Leuven, Leuven, Belgium
- Laboratory of Angiogenesis and Vascular Metabolism, Center for Cancer Biology, VIB, Leuven, Belgium
| | - Daniel Castranova
- Division of Developmental Biology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA
| | - Anca M Cimpean
- Department of Microscopic Morphology/Histology, Angiogenesis Research Center, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania
| | - Ondine Cleaver
- Department of Molecular Biology, Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - George Coukos
- Ludwig Institute for Cancer Research, Department of Oncology, University of Lausanne, Lausanne, Switzerland
| | - George E Davis
- Department of Medical Pharmacology and Physiology, University of Missouri, School of Medicine and Dalton Cardiovascular Center, Columbia, MO, USA
| | - Michele De Palma
- School of Life Sciences, Swiss Federal Institute of Technology, Lausanne, Switzerland
| | - Anna Dimberg
- Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
| | - Ruud P M Dings
- Department of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA
| | | | - Andrew C Dudley
- Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, VA, USA
- Emily Couric Cancer Center, The University of Virginia, Charlottesville, VA, USA
| | - Neil P Dufton
- Vascular Sciences, Imperial Centre for Translational and Experimental Medicine, National Heart and Lung Institute, Imperial College London, London, UK
| | - Sarah-Maria Fendt
- Laboratory of Cellular Metabolism and Metabolic Regulation, VIB Center for Cancer Biology, Leuven, Belgium
- Laboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, KU Leuven and Leuven Cancer Institute, Leuven, Belgium
| | | | - Marcus Fruttiger
- Institute of Ophthalmology, University College London, London, UK
| | - Dai Fukumura
- Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
| | - Bart Ghesquière
- Metabolomics Expertise Center, VIB Center for Cancer Biology, VIB, Leuven, Belgium
- Department of Oncology, Metabolomics Expertise Center, KU Leuven, Leuven, Belgium
| | - Yan Gong
- Department of Ophthalmology, Harvard Medical School, Boston Children's Hospital, Boston, MA, USA
| | - Robert J Griffin
- Department of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA
| | - Adrian L Harris
- Molecular Oncology Laboratories, Oxford University Department of Oncology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
| | - Christopher C W Hughes
- Department of Molecular Biology and Biochemistry, University of California, Irvine, CA, USA
| | - Nan W Hultgren
- Department of Molecular Biology and Biochemistry, University of California, Irvine, CA, USA
| | | | - Melita Irving
- Ludwig Institute for Cancer Research, Department of Oncology, University of Lausanne, Lausanne, Switzerland
| | - Rakesh K Jain
- Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
| | - Raghu Kalluri
- Department of Cancer Biology, Metastasis Research Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Joanna Kalucka
- Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology and Leuven Cancer Institute (LKI), KU Leuven, Leuven, Belgium
- Laboratory of Angiogenesis and Vascular Metabolism, Center for Cancer Biology, VIB, Leuven, Belgium
| | - Robert S Kerbel
- Department of Medical Biophysics, Biological Sciences Platform, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada
| | - Jan Kitajewski
- Department of Physiology and Biophysics, University of Illinois, Chicago, IL, USA
| | - Ingeborg Klaassen
- Ocular Angiogenesis Group, Departments of Ophthalmology and Medical Biology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - Hynda K Kleinmann
- The George Washington University School of Medicine, Washington, DC, USA
| | - Pieter Koolwijk
- Department of Ophthalmology, University of Lausanne, Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, Lausanne, Switzerland
| | - Elisabeth Kuczynski
- Department of Medical Biophysics, Biological Sciences Platform, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada
| | - Brenda R Kwak
- Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland
| | | | - Juan M Melero-Martin
- Department of Cardiac Surgery, Harvard Medical School, Boston Children's Hospital, Boston, MA, USA
| | - Lance L Munn
- Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
| | - Roberto F Nicosia
- Department of Pathology, University of Washington, Seattle, WA, USA
- Pathology and Laboratory Medicine Service, VA Puget Sound Health Care System, Seattle, WA, USA
| | - Agnes Noel
- Laboratory of Tumor and Developmental Biology, GIGA-Cancer, University of Liège, Liège, Belgium
| | - Jussi Nurro
- Department of Biotechnology and Molecular Medicine, University of Eastern Finland, Kuopio, Finland
| | - Anna-Karin Olsson
- Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala Biomedical Center, Uppsala University, Uppsala, Sweden
| | - Tatiana V Petrova
- Department of oncology UNIL-CHUV, Ludwig Institute for Cancer Research Lausanne, Lausanne, Switzerland
| | - Kristian Pietras
- Division of Translational Cancer Research, Department of Laboratory Medicine, Lund, Sweden
| | - Roberto Pili
- Genitourinary Program, Indiana University-Simon Cancer Center, Indianapolis, IN, USA
| | - Jeffrey W Pollard
- Medical Research Council Centre for Reproductive Health, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK
| | - Mark J Post
- Department of Physiology, Maastricht University, Maastricht, The Netherlands
| | - Paul H A Quax
- Einthoven Laboratory for Experimental Vascular Medicine, Department Surgery, LUMC, Leiden, The Netherlands
| | - Gabriel A Rabinovich
- Laboratory of Immunopathology, Institute of Biology and Experimental Medicine, National Council of Scientific and Technical Investigations (CONICET), Buenos Aires, Argentina
| | - Marius Raica
- Department of Microscopic Morphology/Histology, Angiogenesis Research Center, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania
| | - Anna M Randi
- Vascular Sciences, Imperial Centre for Translational and Experimental Medicine, National Heart and Lung Institute, Imperial College London, London, UK
| | - Domenico Ribatti
- Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, Bari, Italy
- National Cancer Institute "Giovanni Paolo II", Bari, Italy
| | - Curzio Ruegg
- Department of Oncology, Microbiology and Immunology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland
| | - Reinier O Schlingemann
- Ocular Angiogenesis Group, Departments of Ophthalmology and Medical Biology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
- Department of Ophthalmology, University of Lausanne, Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, Lausanne, Switzerland
| | - Stefan Schulte-Merker
- Institute of Cardiovascular Organogenesis and Regeneration, Faculty of Medicine, WWU, Münster, Germany
| | - Lois E H Smith
- Department of Ophthalmology, Harvard Medical School, Boston Children's Hospital, Boston, MA, USA
| | - Jonathan W Song
- Department of Mechanical and Aerospace Engineering, The Ohio State University, Columbus, OH, USA
- Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
| | - Steven A Stacker
- Tumour Angiogenesis and Microenvironment Program, Peter MacCallum Cancer Centre and The Sir Peter MacCallum, Department of Oncology, University of Melbourne, Melbourne, VIC, Australia
| | - Jimmy Stalin
- Institute of Cardiovascular Organogenesis and Regeneration, Faculty of Medicine, WWU, Münster, Germany
| | - Amber N Stratman
- Division of Developmental Biology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA
| | - Maureen Van de Velde
- Laboratory of Tumor and Developmental Biology, GIGA-Cancer, University of Liège, Liège, Belgium
| | - Victor W M van Hinsbergh
- Department of Ophthalmology, University of Lausanne, Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, Lausanne, Switzerland
| | - Peter B Vermeulen
- HistoGeneX, Antwerp, Belgium
- Translational Cancer Research Unit, GZA Hospitals, Sint-Augustinus & University of Antwerp, Antwerp, Belgium
| | - Johannes Waltenberger
- Medical Faculty, University of Münster, Albert-Schweitzer-Campus 1, Münster, Germany
| | - Brant M Weinstein
- Division of Developmental Biology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA
| | - Hong Xin
- University of California, San Diego, La Jolla, CA, USA
| | - Bahar Yetkin-Arik
- Ocular Angiogenesis Group, Departments of Ophthalmology and Medical Biology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - Seppo Yla-Herttuala
- Department of Biotechnology and Molecular Medicine, University of Eastern Finland, Kuopio, Finland
| | - Mervin C Yoder
- Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Arjan W Griffioen
- Angiogenesis Laboratory, Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
| |
Collapse
|
7
|
Breasson L, Becattini B, Sardi C, Molinaro A, Zani F, Marone R, Botindari F, Bousquenaud M, Ruegg C, Wymann MP, Solinas G. PI3Kγ activity in leukocytes promotes adipose tissue inflammation and early-onset insulin resistance during obesity. Sci Signal 2017; 10:10/488/eaaf2969. [PMID: 28720716 DOI: 10.1126/scisignal.aaf2969] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The phosphoinositide 3-kinase γ (PI3Kγ) plays a major role in leukocyte recruitment during acute inflammation and has been proposed to inhibit classical macrophage activation by driving immunosuppressive gene expression. PI3Kγ plays an important role in diet-induced obesity and insulin resistance. In seeking to determine the underlying molecular mechanisms, we showed that PI3Kγ action in high-fat diet-induced inflammation and insulin resistance depended largely on its role in the control of adiposity, which was due to PI3Kγ activity in a nonhematopoietic cell type. However, PI3Kγ activity in leukocytes was required for efficient neutrophil recruitment to adipose tissue. Neutrophil recruitment was correlated with proinflammatory gene expression in macrophages in adipose tissue, which triggered insulin resistance early during the development of obesity. Our data challenge the concept that PI3Kγ is a general suppressor of classical macrophage activation and indicate that PI3Kγ controls macrophage gene expression by non-cell-autonomous mechanisms, the outcome of which is context-dependent.
Collapse
Affiliation(s)
- Ludovic Breasson
- Department of Medicine/Physiology, University of Fribourg, 1700 Fribourg, Switzerland
| | - Barbara Becattini
- Department of Medicine/Physiology, University of Fribourg, 1700 Fribourg, Switzerland
| | | | | | - Fabio Zani
- Department of Medicine/Physiology, University of Fribourg, 1700 Fribourg, Switzerland
| | - Romina Marone
- Cancer and Immunobiology Laboratory, Department of Biomedicine, University of Basel, 4058 Basel, Switzerland
| | - Fabrizio Botindari
- Cancer and Immunobiology Laboratory, Department of Biomedicine, University of Basel, 4058 Basel, Switzerland
| | - Mélanie Bousquenaud
- Department of Medicine/Physiology, University of Fribourg, 1700 Fribourg, Switzerland
| | - Curzio Ruegg
- Department of Medicine/Physiology, University of Fribourg, 1700 Fribourg, Switzerland
| | - Matthias P Wymann
- Cancer and Immunobiology Laboratory, Department of Biomedicine, University of Basel, 4058 Basel, Switzerland.
| | - Giovanni Solinas
- Department of Medicine/Physiology, University of Fribourg, 1700 Fribourg, Switzerland.
| |
Collapse
|
8
|
Filipovic N, Ghimire K, Saveljic I, Milosevic Z, Ruegg C. Computational modeling of shear forces and experimental validation of endothelial cell responses in an orbital well shaker system. Comput Methods Biomech Biomed Engin 2015; 19:581-90. [DOI: 10.1080/10255842.2015.1051973] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
9
|
Ciarloni L, Hosseinian S, Monnier-Benoit S, Imaizumi N, Dorta G, Ruegg C. Discovery of a 29-gene panel in peripheral blood mononuclear cells for the detection of colorectal cancer and adenomas using high throughput real-time PCR. PLoS One 2015; 10:e0123904. [PMID: 25876024 PMCID: PMC4395254 DOI: 10.1371/journal.pone.0123904] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2014] [Accepted: 02/27/2015] [Indexed: 12/15/2022] Open
Abstract
Colorectal cancer (CRC) is the second leading cause of cancer-related death in developed countries. Early detection of CRC leads to decreased CRC mortality. A blood-based CRC screening test is highly desirable due to limited invasiveness and high acceptance rate among patients compared to currently used fecal occult blood testing and colonoscopy. Here we describe the discovery and validation of a 29-gene panel in peripheral blood mononuclear cells (PBMC) for the detection of CRC and adenomatous polyps (AP). Blood samples were prospectively collected from a multicenter, case-control clinical study. First, we profiled 93 samples with 667 candidate and 3 reference genes by high throughput real-time PCR (OpenArray system). After analysis, 160 genes were retained and tested again on 51 additional samples. Low expressed and unstable genes were discarded resulting in a final dataset of 144 samples profiled with 140 genes. To define which genes, alone or in combinations had the highest potential to discriminate AP and/or CRC from controls, data were analyzed by a combination of univariate and multivariate methods. A list of 29 potentially discriminant genes was compiled and evaluated for its predictive accuracy by penalized logistic regression and bootstrap. This method discriminated AP >1cm and CRC from controls with a sensitivity of 59% and 75%, respectively, with 91% specificity. The behavior of the 29-gene panel was validated with a LightCycler 480 real-time PCR platform, commonly adopted by clinical laboratories. In this work we identified a 29-gene panel expressed in PBMC that can be used for developing a novel minimally-invasive test for accurate detection of AP and CRC using a standard real-time PCR platform.
Collapse
Affiliation(s)
- Laura Ciarloni
- Diagnoplex SA, Epalinges, Switzerland
- Novigenix SA, Epalinges, Switzerland
| | - Sahar Hosseinian
- Diagnoplex SA, Epalinges, Switzerland
- Novigenix SA, Epalinges, Switzerland
| | | | - Natsuko Imaizumi
- Diagnoplex SA, Epalinges, Switzerland
- National Center for Competence in Research (NCCR), Molecular Oncology, Swiss Institute for Experimental Cancer Research (ISREC)-Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - Gian Dorta
- Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland
| | - Curzio Ruegg
- Novigenix SA, Epalinges, Switzerland
- National Center for Competence in Research (NCCR), Molecular Oncology, Swiss Institute for Experimental Cancer Research (ISREC)-Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
- Department of Medicine, Faculty of Science, University of Fribourg, Fribourg, Switzerland
- * E-mail:
| | | |
Collapse
|
10
|
Lohri C, Schaltegger CSH, VAN DEN Broek M, Wenger RH, Ruegg C, Fink D, Fehr MK, Knuth A, Zweifel M. Neutrophil expression of ICAM1, CXCR1, and VEGFR1 in patients with breast cancer before and after adjuvant chemotherapy. Anticancer Res 2014; 34:4693-4699. [PMID: 25202046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
BACKGROUND Distinct populations of neutrophils have been identified based on the expression of intercellular adhesion molecule 1 (ICAM1, CD54) and chemokine receptor 1 (CXCR1, interleukin 8 receptor α). AIM We analyzed the expression of vascular endothelial growth factor receptor 1 (VEGFR1), a physiological negative regulator of angiogenesis, on distinct populations of neutrophils from the blood of patients before and after adjuvant chemotherapy for breast cancer. MATERIALS AND METHODS Neutrophil populations were distinguished as reverse transmigrated (ICAM1(high)/CXCR1(low)), naïve (ICAM1(low)/CXCR1(high)), or tissue-resident neutrophils (ICAM1(low)/CXCR1(low)), and their VEGFR1 expression quantified. RESULTS Reverse transmigrated ICAM1(high)/CXCR1(low) neutrophilic granulocytes decreased significantly after chemotherapy and these were also the cells with highest mean fluorescence intensity for VEGFR1. CONCLUSION Chemotherapy mainly reduces the number of reverse transmigrated long-lived ICAM1(high)/CXCR1(low) VEGFR1-expressing neutrophils. The decrease of antiangiogenic VEGFR1 may have a potential impact on tumour angiogenesis in patients undergoing adjuvant chemotherapy.
Collapse
Affiliation(s)
| | | | | | - Roland H Wenger
- Institute of Physiology, University of Zurich, Zurich, Switzerland Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland
| | - Curzio Ruegg
- Department of Medicine, Faculty of Science, University of Fribourg, Fribourg, Switzerland
| | - Daniel Fink
- Department of Gynaecology, University Hospital Zurich, Zurich, Switzerland
| | - Mathias K Fehr
- Department of Gynaecology and Obstetrics, Frauenfeld General Hospital, Frauenfeld, Switzerland
| | - Alexander Knuth
- National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar
| | - Martin Zweifel
- Department of Medical Oncology, Bern University Hospital, Bern, Switzerland
| |
Collapse
|
11
|
Ruegg C, Waugh J. Safety and efficacy of topical botulinum toxin type A for the treatment of moderate to severe lateral canthal lines – A review of the U.S. Phase 2b experience. Toxicon 2013. [DOI: 10.1016/j.toxicon.2012.07.161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
12
|
Ten Hagen TLM, Seynhaeve ALB, de Wiel-Ambagtsheer GA, de Bruijn EA, van Tiel ST, Ruegg C, Meyring M, Grell M, Goodman SL, Eggermont AMM. The αVβ3/αVβ5 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model. Int J Cancer 2012; 132:2694-704. [PMID: 23152080 DOI: 10.1002/ijc.27940] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2012] [Accepted: 10/15/2012] [Indexed: 01/13/2023]
Abstract
Isolated limb perfusion (ILP) with melphalan and tumor necrosis factor (TNF)-α is used to treat bulky, locally advanced melanoma and sarcoma. However, TNF toxicity suggests a need for better-tolerated drugs. Cilengitide (EMD 121974), a novel cyclic inhibitor of alpha-V integrins, has both anti-angiogenic and direct anti-tumor effects and is a possible alternative to TNF in ILP. In this study, rats bearing a hind limb soft tissue sarcoma underwent ILP using different combinations of melphalan, TNF and cilengitide in the perfusate. Further groups had intra-peritoneal (i.p.) injections of cilengitide or saline 2 hr before and 3 hr after ILP. A 77% response rate (RR) was seen in animals treated i.p. with cilengitide and perfused with melphalan plus cilengitide. The RR was 85% in animals treated i.p. with cilengitide and ILP using melphalan plus both TNF and cilengitide. Both RRs were significantly greater than those seen with melphalan or cilengitide alone. Histopathology showed that high RRs were accompanied by disruption of tumor vascular endothelium and tumor necrosis. Compared with ILP using melphalan alone, the addition of cilengitide resulted in a three to sevenfold increase in melphalan concentration in tumor but not in muscle in the perfused limb. Supportive in vitro studies indicate that cilengitide both inhibits tumor cell attachment and increases endothelial permeability. Since cilengitide has low toxicity, these data suggest the agent is a good alternative to TNF in the ILP setting.
Collapse
Affiliation(s)
- Timo L M Ten Hagen
- Department of Surgery, Section Surgical Oncology, Laboratory Experimental Surgical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Laurent J, Touvrey C, Botta F, Kuonen F, Ruegg C. Emerging paradigms and questions on pro-angiogenic bone marrow-derived myelomonocytic cells. Int J Dev Biol 2011; 55:527-34. [PMID: 21769777 DOI: 10.1387/ijdb.103228jl] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Cancer-related inflammation has emerged in recent years as a major event contributing to tumor angiogenesis, tumor progression and metastasis formation. Bone marrow-derived and inflammatory cells promote tumor angiogenesis by providing endothelial progenitor cells that differentiate into mature endothelial cells, and by secreting pro-angiogenic factors and remodeling the extracellular matrix to stimulate angiogenesis though paracrine mechanisms. Several bone marrow-derived myelonomocytic cells, including monocytes and macrophages, have been identified and characterized by several laboratories in recent years. While the central role of these cells in promoting tumor angiogenesis, tumor progression and metastasis is nowadays well established, many questions remain open and new ones are emerging. These include the relationship between their phenotype and function, the mechanisms of pro-angiogenic programming, their contribution to resistance to anti-angiogenic treatments and to metastasis and their potential clinical use as biomarkers of angiogenesis and anti-angiogenic therapies. Here, we will review phenotypical and functional aspects of bone marrow-derived myelonomocytic cells and discuss some of the current outstanding questions.
Collapse
Affiliation(s)
- Julien Laurent
- Centre Pluridiscipliniaire d'Oncologie, University of Lausanne, Lausanne, Switzerland
| | | | | | | | | |
Collapse
|
14
|
Luethy A, Stenner F, Lohri C, Muller C, Samaras P, Steiner R, Van Den Broek M, Mischo A, Renner C, Knuth A, Ruegg C, Wenger RH, Zweifel M. Autologous stem cell transplantation: leukapheresis product has anti-angiogenic effects in vivo correlating with neutrophil-derived VEGFR1. Anticancer Res 2011; 31:3115-3124. [PMID: 21965716] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
BACKGROUND High-dose chemotherapy (HDC) followed by autologous stem cell transplantation (ASCT) is used for the treatment of hemato-oncologic malignancies. In this study, we measured the effect of HDC/ASCT on plasma concentrations of antiangiogenic soluble vascular endothelial growth factor receptor 1 (sVEGFR1) and of leukapheresis products (LP) and patient serum on chick chorioallantoic (CAM) angiogenesis. MATERIALS AND METHODS VEGFR1- and CD34-expressing cells of leukapheresis products were analyzed by flow cytometry. Alternatively spliced isoforms of VEGFR1 mRNA were quantified using reverse transcription PCR. RESULTS Plasma concentrations of sVEGFR1 decreased after HDC, but significantly increased after ASCT. In the CAM assay, sera of patients elicited a proangiogenic effect before and after HDC, but a strong antiangiogenic response after ASCT, comparable to that of bevacizumab at therapeutic concentrations. LP contains high concentrations of sVEGFR1, and high density of VEGFR1(+) neutrophilic granulocytes, in which mRNA expression is shifted toward the soluble VEGFR1 isoform. CONCLUSION Neutrophil-derived antiangiogenic sVEGFR1 within the LP may contribute to the therapeutic efficacy of ASCT.
Collapse
Affiliation(s)
- Anita Luethy
- Institute of Physiology and Zurich Center for Integrative Human Physiology ZIHP, University of Zurich, Zurich, Switzerland
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Laurent J, Hull EFV, Touvrey C, Kuonen F, Lan Q, Lorusso G, Doucey MA, Ciarloni L, Imaizumi N, Alghisi GC, Fagiani E, Zaman K, Stupp R, Shibuya M, Delaloye JF, Christofori G, Ruegg C. Proangiogenic Factor PlGF Programs CD11b+ Myelomonocytes in Breast Cancer during Differentiation of Their Hematopoietic Progenitors. Cancer Res 2011; 71:3781-91. [DOI: 10.1158/0008-5472.can-10-3684] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Tumor-mobilized bone marrow–derived CD11b+ myeloid cells promote tumor angiogenesis, but how and when these cells acquire proangiogenic properties is not fully elucidated. Here, we show that CD11b+ myelomonocytic cells develop proangiogenic properties during their differentiation from CD34+ hematopoietic progenitors and that placenta growth factor (PlGF) is critical in promoting this education. Cultures of human CD34+ progenitors supplemented with conditioned medium from breast cancer cell lines or PlGF, but not from nontumorigenic breast epithelial lines, generate CD11b+ cells capable of inducing endothelial cell sprouting in vitro and angiogenesis in vivo. An anti–Flt-1 mAb or soluble Flt-1 abolished the generation of proangiogenic activity during differentiation from progenitor cells. Moreover, inhibition of metalloproteinase activity, but not VEGF, during the endothelial sprouting assay blocked sprouting induced by these proangiogenic CD11b+ myelomonocytes. In a mouse model of breast cancer, circulating CD11b+ cells were proangiogenic in the sprouting assays. Silencing of PlGF in tumor cells prevented the generation of proangiogenic activity in circulating CD11b+ cells, inhibited tumor blood flow, and slowed tumor growth. Peripheral blood of breast cancer patients at diagnosis, but not of healthy individuals, contained elevated levels of PlGF and circulating proangiogenic CD11b+ myelomonocytes. Taken together, our results show that cancer cells can program proangiogenic activity in CD11b+ myelomonocytes during differentiation of their progenitor cells in a PlGF-dependent manner. These findings impact breast cancer biology, detection, and treatment. Cancer Res; 71(11); 3781–91. ©2011 AACR.
Collapse
Affiliation(s)
- Julien Laurent
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| | - Eveline Faes-van't Hull
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| | - Cedric Touvrey
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| | - François Kuonen
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| | - Qiang Lan
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| | - Girieca Lorusso
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| | - Marie-Agnès Doucey
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| | - Laura Ciarloni
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| | - Natsuko Imaizumi
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| | - Gian Carlo Alghisi
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| | - Ernesta Fagiani
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| | - Khalil Zaman
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| | - Roger Stupp
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| | - Masabumi Shibuya
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| | - Jean-François Delaloye
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| | - Gerhard Christofori
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| | - Curzio Ruegg
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
- Authors' Affiliations: 1Division of Experimental Oncology (DEO), 2The Breast Center, Centre Pluridisciplinaire d'Oncologie (CePO), and 3The Breast Center, Department of Obstetrics and Gynecology, 4Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine; 5National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research, Ecole Polytechnique Féderale de Lausanne (ISREC-EPFL-SV), Lausanne; 6Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg; 7Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and 8Tokyo Medical and Dental University, Department of Molecular Oncology, Tokyo, Japan
| |
Collapse
|
16
|
Ciarloni L, Hosseinian S, Monnier-Benoit S, Imaizumi N, Dorta G, Ruegg C. Abstract 3174: Colorectal cancer specific host response signatures achieved by next generation sequencing and multiplex RT-qPCR. Cancer Res 2011. [DOI: 10.1158/1538-7445.am2011-3174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: colorectal cancer (CRC) develops over a period of several years and is often preceded by adenoma formation. Detection rates for colorectal adenoma and early CRC, however, are unsatisfactory due to low compliance towards invasive screening procedures such as colonoscopy. There is a large unmet screening need calling for an accurate, non invasive and cost effective test to screen for early neoplastic and preneoplastic colorectal lesions. We developed a screening test aimed at detecting precancerous lesions and CRC at early stages, based on a multigene expression profiling on peripheral blood mononuclear cells (PBMC).
Methods: 92 colonoscopy screened subjects served as a training set. Colonoscopy revealed 21 patients had CRC, 30 adenomas larger than 1cm and 41 had no detectable lesions. 16 mL of blood was collected from each individual and PBMC were purified using Vacutainer® CPT tubes (Becton Dickinson). Total RNA was extracted and a whole genome expression analysis by digital gene expression TAG profiling (Illumina) was performed on a subset of these 92 subjects. Deep sequencing generated on average 1.5 million reads per sample and they matched to 20288 different transcripts. Different univariate and multivariate statistical methods were then applied in order to find genes differentially expressed between control, adenoma and CRC (pvalue <0.05). 45 candidate genes discovered with TAG profiling were then analytically validated using a multiplex RT qPCR methodology. All candidate genes were normalized with a stable normalization strategy in order to obtain comparable results across assays. An additional set of 57 candidate genes was also added based on literature review and validated using the multiplex RT qPCR methodology. Multiple statistical methods were applied on the normalized PCR data and 43 biomarkers, with significant p-value (<0.01) for most of the methods, were selected. Two distinct molecular signatures were derived from the normalized biomarker combinations based on penalized logistic.
Results: a validation set was defined using random resampling (bootstrapping method), leading to the separation of individuals without lesion from those with CRC (Se 70%, Sp 94%, AUC 0.89) and from those with adenoma larger than 1cm (Se 67%, Sp 87%, AUC 0.80). In addition, as a test set, the organ and disease specificity of these signatures was confirmed by means of patients with other cancer types and inflammatory bowel diseases.
Conclusion: Next generation sequencing is a powerful research tool to define specific signatures for precancerous and early cancerous lesions when coupled to multiplex RT qPCR and normalized with specific reference genes. A prospective, multi-centric, pivotal study is underway in order to validate these results in a larger cohort.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3174. doi:10.1158/1538-7445.AM2011-3174
Collapse
|
17
|
Kuonen F, Touvrey C, Laurent J, Ruegg C. Fc block treatment, dead cells exclusion, and cell aggregates discrimination concur to prevent phenotypical artifacts in the analysis of subpopulations of tumor-infiltrating CD11b(+) myelomonocytic cells. Cytometry A 2011; 77:1082-90. [PMID: 20824631 DOI: 10.1002/cyto.a.20969] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
It is well established that cancer cells can recruit CD11b(+) myeloid cells to promote tumor angiogenesis and tumor growth. Increasing interest has emerged on the identification of subpopulations of tumor-infiltrating CD11b(+) myeloid cells using flow cytometry techniques. In the literature, however, discrepancies exist on the phenotype of these cells (Coffelt et al., Am J Pathol 2010;176:1564-1576). Since flow cytometry analysis requires particular precautions for accurate sample preparation and trustable data acquisition, analysis, and interpretation, some discrepancies might be due to technical reasons rather than biological grounds. We used the syngenic orthotopic 4T1 mammary tumor model in immunocompetent BALB/c mice to analyze and compare the phenotype of CD11b(+) myeloid cells isolated from peripheral blood and from tumors, using six-color flow cytometry. We report here that the nonspecific antibody binding through Fc receptors, the presence of dead cells and cell doublets in tumor-derived samples concur to generate artifacts in the phenotype of tumor-infiltrating CD11b(+) subpopulations. We show that the heterogeneity of tumor-infiltrating CD11b(+) subpopulations analyzed without particular precautions was greatly reduced upon Fc block treatment, dead cells, and cell doublets exclusion. Phenotyping of tumor-infiltrating CD11b(+) cells was particularly sensitive to these parameters compared to circulating CD11b(+) cells. Taken together, our results identify Fc block treatment, dead cells, and cell doublets exclusion as simple but crucial steps for the proper analysis of tumor-infiltrating CD11b(+) cell populations.
Collapse
Affiliation(s)
- Francois Kuonen
- Division of Experimental Oncology, Centre Pluridiscipliniaire d'Oncologie (CePO), Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Faculty of Biology and Medicine, Lausanne, Switzerland
| | | | | | | |
Collapse
|
18
|
Zaman K, Rochlitz C, Ruhstaller T, Thürlimann B, Aebi S, von Moos R, Mamot C, Gabriel N, Rossier-Pansier L, Stupp R, Crowe S, Ruegg C. Abstract P2-16-07: hMMP9 as Predictive Factor for Response and Progression Free Survival in Breast Cancer Patients Treated with Bevacizumab and Pegylated Liposomal Doxorubicin (PLD). Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p2-16-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The anti-angiogenic drug, bevacizumab (Bv), is currently used in the treatment of different malignancies including breast cancer. Many angiogenesis-associated molecules are found in the circulation of cancer patients. Until now, there are no prognostic or predictive factors identified in breast cancer patients treated with Bv. We present here the first results of the prospective monitoring of 6 angiogenesis-related molecules in the peripheral blood of breast cancer patients treated with a combination of Bv and PLD in the phase II trial, SAKK 24/06. Methods: Patients were treated with PLD (20 mg/m2) and Bv (10 mg/kg) on days 1 and 15 of each 4-week cycle for a maximum of 6 cycles, followed by Bv monotherapy maintenance (10 mg/m2 q2 weeks) until progression or severe toxicity. Plasma and serum samples were collected at baseline, after 2 months of therapy, then every 3 months and at treatment discontinuation. Enzyme-linked immunosorbent assays (Quantikine, R&D Systems and Reliatech) were used to measure the expression levels of human vascular endothelial growth factor (hVEGF), placental growth factor (hPlGF), matrix metalloproteinase 9 (hMMP9) and soluble VEGF receptors hsVEGFR-1, hsVEGFR-2 and hsVEGFR-3. The log-transformed data (to reduce the skewness) for each marker was analyzed using an analysis of variance (ANOVA) model to determine if there was a difference between the mean of the subgroups of interest (where α = 0.05). The untransformed data was also analyzed in the same manner as a “sensitivity” check.
Results: 132 blood samples were collected in 41 out of 43 enrolled patients. Baseline levels of the molecules were compared to disease status according to RECIST. There was a statistically significant difference in the mean of the log-transformed levels of hMMP9 between responders [CR+PR] versus the mean in patients with PD (p-value=0.0004, log fold change=0.7536), and between patients with disease control [CR+PR+SD] and those with PD (p-value=<0.0001, log fold change=0.81559), with the log-transformed level of hMMP9 being higher for the responder group. The mean of the log-transformed levels of hsVEGFR-1 was statistically significantly different between patients with disease control [CR+PR+SD] and those with PD (p-value=0.0068, log fold change=-0.6089), where the log-transformed level of hsVEGFR-1 was lower for the responder group. The log-transformed level of hMMP9 at baseline was identified as a significant prognostic factor in terms of progression free survival (PFS): p-value=0.0417, hazard ratio (HR)=0.574 with a corresponding 95% confidence interval (0.336 — 0.979)). No strong correlation was shown either between the log-transformed levels of hsVEGF, hPlGF, hsVEGFR-2 or hsVEGFR-3 and clinical response or the occurrence of severe toxicity, or between the levels of the different molecules.
Conclusions: Our results suggest that baseline plasma level of the matrix metalloproteinase, hMMP9, could predict tumor response and PFS in patients treated with a combination of Bv and PLD. These data justify further investigation in breast cancer patients treated with anti-angiogenic therapy.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-16-07.
Collapse
Affiliation(s)
- K Zaman
- CePO, University Hospital, Lausanne, Switzerland; University Hospital Basel, Switzerland; Kantonsspital St. Gallen, Switzerland; University Hospital Bern, Switzerland; Kantonsspital Chur, Switzerland; Kantonsspital Aarau, Switzerland; University Hospital Zürich, Switzerland; Statistics Unit, SAKK Coordination Center, Bern, Switzerland
| | - C Rochlitz
- CePO, University Hospital, Lausanne, Switzerland; University Hospital Basel, Switzerland; Kantonsspital St. Gallen, Switzerland; University Hospital Bern, Switzerland; Kantonsspital Chur, Switzerland; Kantonsspital Aarau, Switzerland; University Hospital Zürich, Switzerland; Statistics Unit, SAKK Coordination Center, Bern, Switzerland
| | - T Ruhstaller
- CePO, University Hospital, Lausanne, Switzerland; University Hospital Basel, Switzerland; Kantonsspital St. Gallen, Switzerland; University Hospital Bern, Switzerland; Kantonsspital Chur, Switzerland; Kantonsspital Aarau, Switzerland; University Hospital Zürich, Switzerland; Statistics Unit, SAKK Coordination Center, Bern, Switzerland
| | - B Thürlimann
- CePO, University Hospital, Lausanne, Switzerland; University Hospital Basel, Switzerland; Kantonsspital St. Gallen, Switzerland; University Hospital Bern, Switzerland; Kantonsspital Chur, Switzerland; Kantonsspital Aarau, Switzerland; University Hospital Zürich, Switzerland; Statistics Unit, SAKK Coordination Center, Bern, Switzerland
| | - S Aebi
- CePO, University Hospital, Lausanne, Switzerland; University Hospital Basel, Switzerland; Kantonsspital St. Gallen, Switzerland; University Hospital Bern, Switzerland; Kantonsspital Chur, Switzerland; Kantonsspital Aarau, Switzerland; University Hospital Zürich, Switzerland; Statistics Unit, SAKK Coordination Center, Bern, Switzerland
| | - R von Moos
- CePO, University Hospital, Lausanne, Switzerland; University Hospital Basel, Switzerland; Kantonsspital St. Gallen, Switzerland; University Hospital Bern, Switzerland; Kantonsspital Chur, Switzerland; Kantonsspital Aarau, Switzerland; University Hospital Zürich, Switzerland; Statistics Unit, SAKK Coordination Center, Bern, Switzerland
| | - C Mamot
- CePO, University Hospital, Lausanne, Switzerland; University Hospital Basel, Switzerland; Kantonsspital St. Gallen, Switzerland; University Hospital Bern, Switzerland; Kantonsspital Chur, Switzerland; Kantonsspital Aarau, Switzerland; University Hospital Zürich, Switzerland; Statistics Unit, SAKK Coordination Center, Bern, Switzerland
| | - N Gabriel
- CePO, University Hospital, Lausanne, Switzerland; University Hospital Basel, Switzerland; Kantonsspital St. Gallen, Switzerland; University Hospital Bern, Switzerland; Kantonsspital Chur, Switzerland; Kantonsspital Aarau, Switzerland; University Hospital Zürich, Switzerland; Statistics Unit, SAKK Coordination Center, Bern, Switzerland
| | - L Rossier-Pansier
- CePO, University Hospital, Lausanne, Switzerland; University Hospital Basel, Switzerland; Kantonsspital St. Gallen, Switzerland; University Hospital Bern, Switzerland; Kantonsspital Chur, Switzerland; Kantonsspital Aarau, Switzerland; University Hospital Zürich, Switzerland; Statistics Unit, SAKK Coordination Center, Bern, Switzerland
| | - R Stupp
- CePO, University Hospital, Lausanne, Switzerland; University Hospital Basel, Switzerland; Kantonsspital St. Gallen, Switzerland; University Hospital Bern, Switzerland; Kantonsspital Chur, Switzerland; Kantonsspital Aarau, Switzerland; University Hospital Zürich, Switzerland; Statistics Unit, SAKK Coordination Center, Bern, Switzerland
| | - S Crowe
- CePO, University Hospital, Lausanne, Switzerland; University Hospital Basel, Switzerland; Kantonsspital St. Gallen, Switzerland; University Hospital Bern, Switzerland; Kantonsspital Chur, Switzerland; Kantonsspital Aarau, Switzerland; University Hospital Zürich, Switzerland; Statistics Unit, SAKK Coordination Center, Bern, Switzerland
| | - C. Ruegg
- CePO, University Hospital, Lausanne, Switzerland; University Hospital Basel, Switzerland; Kantonsspital St. Gallen, Switzerland; University Hospital Bern, Switzerland; Kantonsspital Chur, Switzerland; Kantonsspital Aarau, Switzerland; University Hospital Zürich, Switzerland; Statistics Unit, SAKK Coordination Center, Bern, Switzerland
| |
Collapse
|
19
|
Tabatabai G, Weller M, Nabors B, Picard M, Reardon D, Mikkelsen T, Ruegg C, Stupp R. Targeting integrins in malignant glioma. Target Oncol 2010; 5:175-81. [PMID: 20820929 DOI: 10.1007/s11523-010-0156-3] [Citation(s) in RCA: 71] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2010] [Accepted: 08/12/2010] [Indexed: 11/26/2022]
Abstract
The integrin family of cell adhesion receptors is emerging as a promising target of anticancer therapy. AlphaVbeta3 and alphaVbeta5 integrins are overexpressed on both glioma cells and tumor vasculature. Cilengitide, the most advanced specific integrin inhibitor in oncology, has shown antitumor activity against glioma in early clinical trials. Durable remissions have been observed in phase I and phase II trials for recurrent glioblastoma (GBM) with both lower and higher doses of cilengitide. Pilot trials in newly diagnosed glioblastoma in conjunction with standard chemoradiotherapy have been encouraging. Preclinical data suggest synergy with concomitant chemo- and radiation therapy. A pivotal phase III study (CENTRIC) in newly diagnosed GBM patients is currently recruiting. This paper summarizes the current understanding of the role of integrins and their inhibition in gliomagenesis. The background and design of ongoing trials are outlined.
Collapse
Affiliation(s)
- Ghazaleh Tabatabai
- Department of Neurology, University Hospital Zurich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland.
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Ruegg C. 194 Biology of tumor angiogenesis and potential biomarkers of angiogenesis. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)70172-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
21
|
|
22
|
Meier R, Mühlethaler-Mottet A, Flahaut M, Coulon A, Fusco C, Louache F, Auderset K, Bourloud KB, Daudigeos E, Ruegg C, Vassal G, Gross N, Joseph JM. The chemokine receptor CXCR4 strongly promotes neuroblastoma primary tumour and metastatic growth, but not invasion. PLoS One 2007; 2:e1016. [PMID: 17925864 PMCID: PMC1995764 DOI: 10.1371/journal.pone.0001016] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2007] [Accepted: 09/19/2007] [Indexed: 11/19/2022] Open
Abstract
Neuroblastoma (NB) is a heterogeneous, and particularly malignant childhood neoplasm in its higher stages, with a propensity to form metastasis in selected organs, in particular liver and bone marrow, and for which there is still no efficient treatment available beyond surgery. Recent evidence indicates that the CXCR4/CXCL12 chemokine/receptor axis may be involved in promoting NB invasion and metastasis. In this study, we explored the potential role of CXCR4 in the malignant behaviour of NB, using a combination of in vitro functional analyses and in vivo growth and metastasis assessment in an orthotopic NB mouse model. We show here that CXCR4 overexpression in non-metastatic CXCR4-negative NB cells IGR-NB8 and in moderately metastatic, CXCR4 expressing NB cells IGR-N91, strongly increased tumour growth of primary tumours and liver metastases, without altering the frequency or the pattern of metastasis. Moreover shRNA-mediated knock-down experiments confirmed our observations by showing that silencing CXCR4 in NB cells impairs in vitro and almost abrogates in vivo growth. High levels of CXCL12 were detected in the mouse adrenal gland (the primary tumour site), and in the liver suggesting a paracrine effect of host-derived CXCL12 on NB growth. In conclusion, this study reveals a yet unreported NB-specific predominant growth and survival-promoting role of CXCR4, which warrants a critical reconsideration of the role of CXCR4 in the malignant behaviour of NB and other cancers.
Collapse
Affiliation(s)
- Roland Meier
- Department of Paediatrics, Paediatric Oncology Research, University Hospital Centre Hospitalier Universitaire Vaudois Lausanne (CHUV), Lausanne, Switzerland
| | - Annick Mühlethaler-Mottet
- Department of Paediatrics, Paediatric Oncology Research, University Hospital Centre Hospitalier Universitaire Vaudois Lausanne (CHUV), Lausanne, Switzerland
| | - Marjorie Flahaut
- Department of Paediatrics, Paediatric Oncology Research, University Hospital Centre Hospitalier Universitaire Vaudois Lausanne (CHUV), Lausanne, Switzerland
| | - Aurélie Coulon
- Department of Paediatrics, Paediatric Oncology Research, University Hospital Centre Hospitalier Universitaire Vaudois Lausanne (CHUV), Lausanne, Switzerland
| | - Carlo Fusco
- Division of Experimental Pathology, University Institute of Pathology, Lausanne, Switzerland
| | | | - Katya Auderset
- Department of Paediatrics, Paediatric Oncology Research, University Hospital Centre Hospitalier Universitaire Vaudois Lausanne (CHUV), Lausanne, Switzerland
| | - Katia Balmas Bourloud
- Department of Paediatrics, Paediatric Oncology Research, University Hospital Centre Hospitalier Universitaire Vaudois Lausanne (CHUV), Lausanne, Switzerland
| | - Estelle Daudigeos
- Unité Propre de Recherche de l'Enseignement Supérieur EA3535, Institut Gustave Roussy, Villejuif, France
| | - Curzio Ruegg
- Division of Experimental Oncology, Multidisciplinary Oncology Centre (CePO), Lausanne Cancer Centre, Lausanne, Switzerland
| | - Gilles Vassal
- Unité Propre de Recherche de l'Enseignement Supérieur EA3535, Institut Gustave Roussy, Villejuif, France
| | - Nicole Gross
- Department of Paediatrics, Paediatric Oncology Research, University Hospital Centre Hospitalier Universitaire Vaudois Lausanne (CHUV), Lausanne, Switzerland
- * To whom correspondence should be addressed. E-mail:
| | - Jean-Marc Joseph
- Department of Paediatrics, University Hospital Centre Hospitalier Universitaire Vaudois Lausanne (CHUV) Surgery Unit, Lausanne, Switzerland
| |
Collapse
|
23
|
Ruegg C, Mutter N. Anti-angiogenic therapies in cancer: achievements and open questions. Bull Cancer 2007; 94:753-62. [PMID: 17878094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2007] [Accepted: 03/24/2007] [Indexed: 05/17/2023]
Abstract
The approval in 2004 of bevacizumab (Avastin), a neutralizing monoclonal antibody directed against vascular endothelial growth factor (VEGF) as the first anti-angiogenic systemic drug to treat cancer patients validated the notion introduced 33 years earlier by Dr. Judah Folkman, that inhibition of tumor angiogenesis might be a valid approach to control tumor growth. Anti-angiogenic therapy was greeted in the clinic a major step forward in cancer treatment. At the same time this success recently boosted the field to the quest for new anti-angiogenic targets and drugs. In spite of this success, however, some old questions in the field have remained unanswered and new ones have emerged. They include the identification for surrogate markers of angiogenesis and anti-angiogenesis, the understanding about how anti-angiogenic therapy and chemotherapy synergize, the characterization of the biological consequences of sustained suppression of angiogenesis on tumor biology and normal tissue homeostasis, and the mechanisms of tumor escape from anti-angiogenesis. In this review we summarize some of these outstanding questions, and highlight future challenges in clinical, translational and experimental research in anti-angiogenic therapy that need to be addressed in order to improve current treatments and to design new drugs.
Collapse
Affiliation(s)
- Curzio Ruegg
- Division of Experimental Oncology, Centre Pluridisciplinaire d'Oncologie (CePO), and Swiss Institute for Experimental Cancer Research (ISREC), NCCR molecular Oncology, Chemin des Boveresses, CH-1066 Epalinges, Switzerland.
| | | |
Collapse
|
24
|
|
25
|
Broillet A, Hantson J, Ruegg C, Messager T, Schneider M. Assessment of microvascular perfusion changes in a rat breast tumor model using SonoVue to monitor the effects of different anti-angiogenic therapies. Acad Radiol 2005; 12 Suppl 1:S28-33. [PMID: 16106543 DOI: 10.1016/j.acra.2005.02.021] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
26
|
Dormond O, Bezzi M, Mariotti A, Ruegg C. Prostaglandin E2 promotes integrin alpha Vbeta 3-dependent endothelial cell adhesion, rac-activation, and spreading through cAMP/PKA-dependent signaling. J Biol Chem 2002; 277:45838-46. [PMID: 12237321 DOI: 10.1074/jbc.m209213200] [Citation(s) in RCA: 121] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
We have recently reported that the inhibition of endothelial cell COX-2 by non-steroidal anti-inflammatory drugs suppresses alpha(V)beta(3)- (but not alpha(5)beta(1)-) dependent Rac activation, endothelial cell spreading, migration, and angiogenesis (Dormond, O., Foletti, A., Paroz, C., and Ruegg, C. (2001) Nat. Med. 7, 1041-1047). Here we investigated the role of the COX-2 metabolites PGE(2) and TXA2 in regulating human umbilical vein endothelial cell (HUVEC) adhesion and spreading. We report that PGE(2) accelerated alpha(V)beta(3)-mediated HUVEC adhesion and promoted Rac activation and cell spreading, whereas the TXA2 agonist retarded adhesion and inhibited spreading. We show that the cAMP level and the cAMP-regulated protein kinase A (PKA) activity are critical mediators of these PGE(2) effects. alpha(V)beta(3)-mediated adhesion induced a transient COX-2-dependent rise in cAMP levels, whereas the cell-permeable cAMP analogue 8-brcAMP accelerated adhesion, promoted Rac activation, and cell spreading in the presence of the COX-2 inhibitor NS-398. Pharmacological inhibition of PKA completely blocked alpha(V)beta(3)-mediated adhesion. A constitutively active Rac mutant (L61Rac) rescued alpha(V)beta(3)-dependent spreading in the presence of NS398 or, but did not accelerate adhesion, whereas a dominant negative Rac mutant (N17Rac) suppressed spreading without affecting adhesion. alpha(5)beta(1)-mediated HUVEC adhesion, Rac activation, and spreading were not affected by PGE(2), 8-brcAMP, or the inhibition of PKA. In conclusion, these results demonstrate that PGE(2) accelerates alpha(V)beta(3)-mediated endothelial cell adhesion through cAMP-dependent PKA activation and induces alpha(V)beta(3)-dependent spreading via cAMP- and PKA-dependent Rac activation and may contribute to the further understanding of the regulation of vascular integrins alpha(V)beta(3) by COX-2/PGE(2) during tumor angiogenesis and inflammation.
Collapse
Affiliation(s)
- Olivier Dormond
- Centre Pluridisciplinaire d'Oncologie (CePO), University of Lausanne Medical School, CH-1011 Lausanne, Switzerland
| | | | | | | |
Collapse
|
27
|
Dormond O, Lejeune FJ, Ruegg C. Modulation of cdk2, cyclin D1, p16INK4a, p21WAF and p27Kip1 expression in endothelial cells by TNF/IFN gamma. Anticancer Res 2002; 22:3159-63. [PMID: 12530059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/28/2023]
Abstract
BACKGROUND Regional administration of high doses of tumor necrosis factor (TNF) and interferon gamma (IFN gamma) to metastatic melanoma patients causes selective disruption of the tumor vasculature. This effect is paralleled by decreased endothelial cell proliferation and suppressed integrin alpha V beta 3-mediated adhesion in vitro. Overexpression of the cyclin-dependent kinase (cdk) inhibitory protein p16INK4a was reported to interfere with integrin alpha V beta 3-dependent melanoma cell adhesion. MATERIALS AND METHODS TNF- and IFN gamma-treated HUVEC were analyzed for cell cycle progression and for protein expression by flow cytometry and Western blotting, respectively. p16INK4a was overexpressed by transient transfection, and HUVEC adhesion was tested in short-term adhesion assays. RESULTS TNF and IFN gamma synergistically induced a G1 arrest associated with reduced levels of cyclin D1 and cdk2, and increased expression of the cdk inhibitors p16INK4a, p21WAF and p27Kip1. p16INK4a overexpression, however, had no effect on alpha V beta 3-mediated adhesion. CONCLUSION These results implicate the down-regulation of cyclin D1 and cdk-2, and up-regulation of p16INK4a, p21WAF and p27Kip1 in the suppression of endothelial cell proliferation induced by TNF/IFN gamma and demonstrate that increased p16INK4a levels are not sufficient to suppress alpha V beta 3-mediated endothelial cell adhesion.
Collapse
Affiliation(s)
- Olivier Dormond
- Centre Pluridisciplinaire d'Oncologie (CePO), University of Lausanne Medical School, CH-1011 Lausanne, Switzerland
| | | | | |
Collapse
|
28
|
Andre F, Andersen M, Wolfers J, Lozier A, Raposo G, Serra V, Ruegg C, Flament C, Angevin E, Amigorena S, Zitvogel L. Exosomes in cancer immunotherapy: preclinical data. Adv Exp Med Biol 2002; 495:349-54. [PMID: 11774591 DOI: 10.1007/978-1-4615-0685-0_49] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- F Andre
- Immunology Unit, Institut Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Abstract
A 71-year-old female patient was hospitalized with membranous laryngopharyngitis typical of classical diphtheria. A toxigenic strain of Corynebacterium ulcerans was isolated from the throat. The patient was treated for 6 days with amoxicillin-clavulanic acid and recovered without complications. This second reported case of diphtheric laryngopharyngitis caused by C. ulcerans in Switzerland is a reminder that C. ulcerans should be included as a possible agent in patients with classical diphtheria symptoms.
Collapse
Affiliation(s)
- D Kaufmann
- Dept. of Otorhinolaryngology, University Hospital of Zurich, Switzerland
| | | | | |
Collapse
|
30
|
Nomeir AA, Ruegg C, Shoemaker M, Favreau LV, Palamanda JR, Silber P, Lin CC. Inhibition of CYP3A4 in a rapid microtiter plate assay using recombinant enzyme and in human liver microsomes using conventional substrates. Drug Metab Dispos 2001; 29:748-53. [PMID: 11302943] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023] Open
Abstract
Cytochrome P450 inhibition studies are performed in the pharmaceutical industry in the discovery stage to screen candidates that may have the potential for clinical drug-drug interactions. A 96-well microtiter plate assay using recombinant cytochrome P450 (Supersomes) has been used to increase the overall throughput. The IC(50) values for the inhibition of CYP3A4 by 52 new chemical entities (NCEs) were determined using the Supersomes assay with resorufin benzyl ether as a substrate, and the data were compared with those obtained in human liver microsomes (HLM) using midazolam as a substrate. Among the 52 compounds tested, 25 showed IC(50) values within a 5-fold difference in the two assays. For all compounds that showed a >5-fold difference, the IC(50) values in the Supersomes assay were lower than those obtained in HLM, except for one compound. Further studies suggested that this discrepancy was not related to difference in protein concentrations between the two assays. In addition, the IC(50) values for 16 compounds with a wide range of inhibition potency were determined in HLM using testosterone and dextromethorphan as substrates. The results showed an 80 to 93% match within a 5-fold difference between the three probe substrates. However, for certain compounds including ketoconazole, there were substrate-dependent differences in the inhibition. The results suggest that the difference between the Supersomes and HLM could be partially attributed to differences in the substrate used, and to metabolism by other cytochrome P450s present in the HLM but not in the Supersomes. Furthermore, multiple CYP3A4 substrates should be used to improve the reliability of estimating potential drug-drug interaction of NCEs.
Collapse
Affiliation(s)
- A A Nomeir
- Exploratory Drug Metabolism, Department of Drug Metabolism and Pharmacokinetics, Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA.
| | | | | | | | | | | | | |
Collapse
|
31
|
Hauzenberger D, Hultenby K, Sumitran S, Ruegg C, Klominek J. Induction of transendothelial migration in normal and malignant human T lymphocytes. Anticancer Res 2000; 20:2601-11. [PMID: 10953332] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
Activated CD 3+ enriched human peripheral blood T cells exhibited potent capacity for transendothelial migration through HUVEC layers in the absence of T cell ***. In contrast, malignant human T cell lines *** no or negligible ability of transendothelial migration in the absence of chemoattractants. Time lapse studies of transendothelial migration of activated CD 3+ enriched peripheral blood T cells through a HUVEC layer showed that the first T cells were detected in the lower compartment of a tissue culture insert after 1 hour and that migration increased to reach a maximum of 25 x 10(4) T cells/hr after 24 hours. Adhesion assays of human T cell lines demonstrated that all T cell lines were capable of adhesion to HUVEC and that adhesion of T cells to HUVECs was primarily mediated by CD11a/CD18 and ICAM-1 interactions. Furthermore, transendothelial migration of CD 3+ enriched human peripheral blood T cells was inhibited by pretreating the T cells with anti-CD 18 monoclonal antibodies. The inability of malignant T cells to migrate through HUVEC layers in the absence of chemoattractants was not due to poor motility per se, since both normal and malignant T cells migrated well on extracellular matrix components as determined by using Boyden chambers. Crosslinking of alpha 1 beta 2 and alpha 4 beta 1 with immobilized monoclonal antibodies induced motile behaviour in activated CD 3 enriched human peripheral blood T cells but not in malignant T cell lines. In conclusion, the differences in the ability of transendothelial migration between normal and malignant human T cells in the absence of chemoattractants is primarily due to the differences in the capacity of alpha 1 beta 2 and alpha 4 beta 1 to trigger motile behaviour in the separate cell types.
Collapse
Affiliation(s)
- D Hauzenberger
- Laboratory of the Centre Pluridiscipllnaire d'Oncologie (CPO), Swiss Institute for Experimental Cancer Research (ISREC), Epalinges, Switzerland
| | | | | | | | | |
Collapse
|
32
|
Abstract
The activation of the transcription factor NF-kappaB often results in protection against apoptosis. In particular, pro-apoptotic tumor necrosis factor (TNF) signals are blocked by proteins that are induced by NF-kappaB such as TNFR-associated factor 1 (TRAF1). Here we show that TRAF1 is cleaved after Asp-163 when cells are induced to undergo apoptosis by Fas ligand (FasL). The C-terminal cleavage product blocks the induction of NF-kappaB by TNF and therefore functions as a dominant negative (DN) form of TRAF1. Our results suggest that the generation of DN-TRAF1 is part of a pro-apoptotic amplification system to assure rapid cell death.
Collapse
Affiliation(s)
- M Irmler
- Institute of Biochemistry, University of Lausanne, Chemin des Boveresses 155, CH-1066, Epalinges, Switzerland
| | | | | | | | | |
Collapse
|
33
|
Ruegg C, Oguey D, Lejeune F. Death to endothelial cells, death to melanoma? Melanoma Res 1999; 9:2-3. [PMID: 10338328] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Affiliation(s)
- C Ruegg
- Multidisciplinary Oncology Centre CHUV, Lausanne, Switzerland
| | | | | |
Collapse
|
34
|
Peshwa MV, Shi JD, Ruegg C, Laus R, van Schooten WC. Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate 1998; 36:129-38. [PMID: 9655265 DOI: 10.1002/(sici)1097-0045(19980701)36:2<129::aid-pros8>3.0.co;2-d] [Citation(s) in RCA: 86] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
BACKGROUND Most strategies in cancer immunotherapy are aimed at the induction of a strong cellular immune response against the tumor. Particularly, CD8+ T lymphocytes have been proven in multiple animal models to be critical for the eradication of solid tumors. METHODS We used a population of peripheral blood-derived antigen-presenting cells (APC), containing dendritic cells (DC), to generate prostate tumor-specific CD8+ T cells. Selected peptides from prostatic acid phosphatase (PAP), a prostate tissue-specific antigen, were shown to bind HLA-A2. A high-affinity peptide was used to generate peptide-specific CD8+ cytolytic T lymphocytes (CTL) from the peripheral blood of healthy donors. RESULTS The obtained PAP-peptide-specific CTL lysed peptide-coated target cells, vaccinia-infected target cells, and HLA-A2-positive prostate-tumor cells in vitro in an antigen-specific manner. CONCLUSIONS Our results indicate that CTL precursors to the PAP gene product exist and could be potentially recruited to elicit an antitumor response. Thus, PAP is a suitable antigen for inclusion in prostate cancer vaccines.
Collapse
Affiliation(s)
- M V Peshwa
- Dendreon Corporation, Mountain View, California 94043, USA.
| | | | | | | | | |
Collapse
|
35
|
Soares LR, Rivas A, Ruegg C, Engleman EG. Differential response of CD4+ V7+ and CD4+ V7- T cells to T cell receptor-dependent signals: CD4+ V7+ T cells are co-stimulation independent and anti-V7 antibody blocks the induction of anergy by bacterial superantigen. Eur J Immunol 1997; 27:1413-21. [PMID: 9209493 DOI: 10.1002/eji.1830270618] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
V7 is a novel cell surface glycoprotein that is expressed on 25% of circulating T lymphocytes. This molecule appears to play a critical role in T cell activation based on the observation that a monoclonal anti-V7 antibody inhibits T cell receptor (TCR)-dependent interleukin-2 (IL-2) production and proliferation of T cells. In the current study, CD4+ V7+ and CD4+ V7- T cells were separated from one another and their response to various stimuli analyzed. Although there were only minor differences between the two subsets in the expression of activation/differentiation markers, including CD45RA and R0 isotypes, when exposed to immobilized anti-CD3 or anti-TCR antibodies in the absence of APC, CD4+ V7+ T cells alone produced IL-2 and proliferated vigorously. By contrast, CD4+ V7- cells responded poorly to such stimuli, but they recovered their capacity to respond if antigen-presenting cells (APC) or anti-CD28-antibody were added to the cultures. The enhancement of the V7- T cell response by APC appears to be related to augmentation of TCR signals because the effect could be blocked by antibodies against molecules on APC [major histocompatibility (MHC) class II, CD86] that are known to up-regulate such signals through their interaction with counter-receptors on T cells. To assess the role of V7 in a system independent of co-stimulation, CD4+ T cells were stimulated with the bacterial superantigens, staphylococcal enterotoxins A and B. The cells responded by proliferating and then becoming anergic. Addition of anti-V7 antibody at the initiation of culture with superantigen did not inhibit cellular proliferation but prevented T cells from becoming anergic, while addition of anti-CD28 antibody had no effect on either proliferation or anergy induction. These results indicate that V7 and CD28 mediate distinct intracellular signals and suggest that V7 functions to preserve T cell reactivity whether the stimulus is mitogenic or anergizing.
Collapse
MESH Headings
- Adult
- Antibodies, Blocking/pharmacology
- Antibodies, Monoclonal/pharmacology
- Antigen-Presenting Cells/immunology
- Antigen-Presenting Cells/metabolism
- Antigens, Bacterial/pharmacology
- Antigens, CD
- Antigens, Differentiation, T-Lymphocyte/immunology
- Antigens, Differentiation, T-Lymphocyte/physiology
- Bacterial Toxins
- CD3 Complex/metabolism
- CD4-Positive T-Lymphocytes/immunology
- Clonal Anergy/drug effects
- Enterotoxins/pharmacology
- Humans
- Immunophenotyping
- Interleukin-2/metabolism
- Lymphocyte Activation/drug effects
- Membrane Glycoproteins/immunology
- Membrane Glycoproteins/physiology
- Receptors, Antigen, T-Cell, alpha-beta/physiology
- Staphylococcus aureus/immunology
- Superantigens/pharmacology
Collapse
Affiliation(s)
- L R Soares
- Department of Pathology, Stanford University School of Medicine, CA 94305, USA
| | | | | | | |
Collapse
|
36
|
Edouard A, Dartayet B, Ruegg C, Samii K. The use of calcium antagonists to treat intra-operative hypertension--evaluation of efficacy and safety of a new dihydropyridine derivative, intravenous isradipine, during abdominal surgery. Ugeskr Laeger 1991; 8:351-8. [PMID: 1834462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Twenty-three patients who developed intraoperative hypertension (mean arterial pressure greater than 110 mmHg) during abdominal surgery under balanced general anaesthesia were randomly assigned to two groups. The isradipine group (n = 12) received 0.5 mg of isradipine, and the placebo group (n = 11) received 10 ml of isradipine solvent over a 5-min period in a blind manner. Arterial pressure was recorded 12 min after the injection was started. If the mean arterial pressure had not decreased by at least 10% at 12 min, patients received in an open manner 0.5 mg of isradipine. None of the patients in the isradipine group received isradipine in an open manner, in contrast with nine of the 11 patients in the placebo group (P less than 0.0001, Fisher's exact test). During both the blind period and the open trial, isradipine induced a 40% decrease in systolic, diastolic, and mean arterial pressures within the first two min of infusion. Arterial pressure remained below the pre-isradipine injection values for at least 45 min. Transient hypotension (mean arterial pressure less than 70 mmHg) was noted in 6/21 patients (29%). Mean heart rate remained statistically unchanged during the decrease in arterial pressure in both groups, but a tachycardia (increase in heart rate greater than 20 beats min-1) was noted in 4/21 patients (19%). This study indicates that intravenous isradipine is an effective therapy with sustained efficacy for intraoperative hypertension during abdominal surgery. The safety of its use needs a close monitoring of arterial pressure.
Collapse
Affiliation(s)
- A Edouard
- Départment d'Anesthésie-Réanimation, Université de Paris-Sud, Hôpital de Bicêtre, Le Kremlin, Bicêtre, France
| | | | | | | |
Collapse
|
37
|
Stoeck M, Ruegg C, Miescher S, Carrel S, Cox D, Von Fliedner V, Alkan S. Comparison of the immunosuppressive properties of milk growth factor and transforming growth factors beta 1 and beta 2. The Journal of Immunology 1989. [DOI: 10.4049/jimmunol.143.10.3258] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Abstract
The effects of the newly isolated bovine milk growth factor (MGF) which shows N-terminal homology to transforming growth factor beta 2 were compared with the effects of porcine transforming growth factor beta 1 and beta 2 (pTGF-beta 1 and -beta 2) on human T lymphocyte activation. Freshly isolated human PBMC were stimulated with either PHA, anti-CD3 + phorbol-12,13-dibutyrate (PDBu), or with a combination of ionomycin + PDBu. MGF, pTGF-beta 1, and pTGF-beta 2 decreased mitogen-induced [3H]thymidine incorporation by 30 to 75% in a dose-dependent manner. The maximum degree of inhibition was obtained at 1 ng/ml (40 pM) and could not be increased by increasing the concentration of teh transforming growth factor 10-fold. Stimulation of fresh T cells with the recall Ag tetanus toxoid was also inhibited (85%) by MGF at pM concentrations as was the proliferation of a human T cell clone specific for purified protein derivative. The effects of MGF and pTGF-beta 1 on anti-CD3-mediated increase of intracellular Ca2+ (Cai2+) was investigated by using the Fura-2 method. Neither MGF nor pTGF-beta 1 inhibited this increase in Cai2+ induced by a mitogenic concentration of anti-CD3 antibody. In order to determine whether TGF-beta preferentially inhibited the CD4+ or CD8+ subpopulation of human T cells, a limiting dilution analysis system, which allows every T cell to proliferate, was used. pTGF-beta 1 at a concentration of 5 ng/ml decreased the frequency of proliferating T cell precursors of both the CD4+ and CD8+ subsets to a similar extent. Furthermore, MGF, pTGF-beta 1, and pTGF-beta 2 also decreased IL-2 mediated [3H]thymidine incorporation into human PBL Con A blasts and the IL-4-mediated [3H]thymidine incorporation of purified T lymphocytes costimulated with PDBu by 70%. In conclusion, bovine MGF exerts suppressive effects on human T cells stimulated with Ag, mitogens, or interleukins, and the degree of T cell suppression is similar (or identical) to those of pTGF-beta 1 or -beta 2.
Collapse
Affiliation(s)
- M Stoeck
- Ludwig Institute for Cancer Research, Lausanne Branch, Epalinges, Switzerland
| | - C Ruegg
- Ludwig Institute for Cancer Research, Lausanne Branch, Epalinges, Switzerland
| | - S Miescher
- Ludwig Institute for Cancer Research, Lausanne Branch, Epalinges, Switzerland
| | - S Carrel
- Ludwig Institute for Cancer Research, Lausanne Branch, Epalinges, Switzerland
| | - D Cox
- Ludwig Institute for Cancer Research, Lausanne Branch, Epalinges, Switzerland
| | - V Von Fliedner
- Ludwig Institute for Cancer Research, Lausanne Branch, Epalinges, Switzerland
| | - S Alkan
- Ludwig Institute for Cancer Research, Lausanne Branch, Epalinges, Switzerland
| |
Collapse
|
38
|
Stoeck M, Ruegg C, Miescher S, Carrel S, Cox D, Von Fliedner V, Alkan S. Comparison of the immunosuppressive properties of milk growth factor and transforming growth factors beta 1 and beta 2. J Immunol 1989; 143:3258-65. [PMID: 2530275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The effects of the newly isolated bovine milk growth factor (MGF) which shows N-terminal homology to transforming growth factor beta 2 were compared with the effects of porcine transforming growth factor beta 1 and beta 2 (pTGF-beta 1 and -beta 2) on human T lymphocyte activation. Freshly isolated human PBMC were stimulated with either PHA, anti-CD3 + phorbol-12,13-dibutyrate (PDBu), or with a combination of ionomycin + PDBu. MGF, pTGF-beta 1, and pTGF-beta 2 decreased mitogen-induced [3H]thymidine incorporation by 30 to 75% in a dose-dependent manner. The maximum degree of inhibition was obtained at 1 ng/ml (40 pM) and could not be increased by increasing the concentration of teh transforming growth factor 10-fold. Stimulation of fresh T cells with the recall Ag tetanus toxoid was also inhibited (85%) by MGF at pM concentrations as was the proliferation of a human T cell clone specific for purified protein derivative. The effects of MGF and pTGF-beta 1 on anti-CD3-mediated increase of intracellular Ca2+ (Cai2+) was investigated by using the Fura-2 method. Neither MGF nor pTGF-beta 1 inhibited this increase in Cai2+ induced by a mitogenic concentration of anti-CD3 antibody. In order to determine whether TGF-beta preferentially inhibited the CD4+ or CD8+ subpopulation of human T cells, a limiting dilution analysis system, which allows every T cell to proliferate, was used. pTGF-beta 1 at a concentration of 5 ng/ml decreased the frequency of proliferating T cell precursors of both the CD4+ and CD8+ subsets to a similar extent. Furthermore, MGF, pTGF-beta 1, and pTGF-beta 2 also decreased IL-2 mediated [3H]thymidine incorporation into human PBL Con A blasts and the IL-4-mediated [3H]thymidine incorporation of purified T lymphocytes costimulated with PDBu by 70%. In conclusion, bovine MGF exerts suppressive effects on human T cells stimulated with Ag, mitogens, or interleukins, and the degree of T cell suppression is similar (or identical) to those of pTGF-beta 1 or -beta 2.
Collapse
Affiliation(s)
- M Stoeck
- Ludwig Institute for Cancer Research, Lausanne Branch, Epalinges, Switzerland
| | | | | | | | | | | | | |
Collapse
|